HUTCHMED (00013.HK): Presents HMPL-A830 Preclinical Data at ENA
NewTimeSpace News: On 19 November 2026, HUTCHMED (China) Limited (stock code: 13) announced on a voluntary basis that it presented preclinical data for HMPL-A830 at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held in Barcelona, Spain, from 18 to 20 November 2026.
HMPL-A830 is a first-in-class antibody-targeted drug conjugate candidate consisting of a highly selective, potent KRAS small-molecule inhibitor payload linked to an anti-epidermal growth factor receptor antibody. It is designed to deliver the KRAS inhibitor directly to EGFR-expressing tumours and block both EGFR and KRAS signalling pathways, addressing resistance and systemic toxicity associated with such inhibition.
In vitro studies showed that its pan-KRAS payload blocks both the active and inactive states of KRAS, with potent antiproliferative activity observed across 55 tumour cell lines covering G12C, G12D, G12V and G13D mutations and wild-type amplification. In mouse models, the drug showed dose-dependent antitumour efficacy in various EGFR-positive tumour models carrying KRAS mutations and achieved more durable tumour regression than a KRAS G12C inhibitor.
An ongoing global Phase I trial is at the Ia stage, evaluating the safety and efficacy of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumours.
- SIHUAN PHARM (00460.HK): bireociclib indication added to national NRDL
- HUTCHMED (00013.HK): Two of Three Drugs Add NRDL Indications
- HUTCHMED (00013.HK): Sovleplenib Wins FDA Orphan Drug Status for AIHA
- HUTCHMED (00013.HK): savolitinib+osimertinib filings accepted in Europe, Japan
- HUTCHMED (00013.HK): Sovleplenib Wins FDA Orphan Drug Status for Primary ITP